Analysts believe that if approved, VX-548 could generate ove...

Analysts believe that if approved, VX-548 could generate over $5B in annual sales for Vertex. Despite the trials not showing superiority over opioids, the safety and addiction advantage of the drug is seen as a significant benefit.